These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24650297)

  • 1. Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study.
    Rogler A; Hoja S; Giedl J; Ekici AB; Wach S; Taubert H; Goebell PJ; Wullich B; Stöckle M; Lehmann J; Petsch S; Hartmann A; Stoehr R
    BMC Cancer; 2014 Mar; 14():214. PubMed ID: 24650297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
    Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
    J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of tumor suppressor MTUS1/ATIP is associated with enhanced proliferation, poor differentiation and poor prognosis in oral tongue squamous cell carcinoma.
    Ding X; Zhang N; Cai Y; Li S; Zheng C; Jin Y; Yu T; Wang A; Zhou X
    Mol Oncol; 2012 Feb; 6(1):73-80. PubMed ID: 22153618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.
    Boman K; Segersten U; Ahlgren G; Eberhard J; Uhlén M; Jirström K; Malmström PU
    BMC Urol; 2013 Apr; 13():17. PubMed ID: 23565664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
    Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
    J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
    Samaratunga H; Khoo K
    Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
    Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
    Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP.
    Di Benedetto M; Bièche I; Deshayes F; Vacher S; Nouet S; Collura V; Seitz I; Louis S; Pineau P; Amsellem-Ouazana D; Couraud PO; Strosberg AD; Stoppa-Lyonnet D; Lidereau R; Nahmias C
    Gene; 2006 Oct; 380(2):127-36. PubMed ID: 16887298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis.
    Mhawech-Fauceglia P; Fischer G; Alvarez V; Ahmed A; Herrmann FR
    BJU Int; 2007 Nov; 100(5):1182-7. PubMed ID: 17645415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder.
    Santos LL; Amaro T; Pereira SA; Lameiras CR; Lopes P; Bento MJ; Oliveira J; Criado B; Lopes CS
    Eur J Surg Oncol; 2003 Feb; 29(1):74-80. PubMed ID: 12559081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
    Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
    Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact.
    Sangoi AR; Higgins JP; Rouse RV; Schneider AG; McKenney JK
    Mod Pathol; 2009 May; 22(5):660-7. PubMed ID: 19270645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of TP53 splice variants in two novel papillary urothelial cancer cell lines.
    Koch A; Hatina J; Rieder H; Seifert HH; Huckenbeck W; Jankowiak F; Florl AR; Stoehr R; Schulz WA
    Cell Oncol (Dordr); 2012 Aug; 35(4):243-57. PubMed ID: 22669776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation analysis of the 8p22 candidate tumor suppressor gene ATIP/MTUS1 in hepatocellular carcinoma.
    Di Benedetto M; Pineau P; Nouet S; Berhouet S; Seitz I; Louis S; Dejean A; Couraud PO; Strosberg AD; Stoppa-Lyonnet D; Nahmias C
    Mol Cell Endocrinol; 2006 Jun; 252(1-2):207-15. PubMed ID: 16650523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
    Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
    Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
    Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y
    Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.
    Guo CC; Dadhania V; Zhang L; Majewski T; Bondaruk J; Sykulski M; Wronowska W; Gambin A; Wang Y; Zhang S; Fuentes-Mattei E; Kamat AM; Dinney C; Siefker-Radtke A; Choi W; Baggerly KA; McConkey D; Weinstein JN; Czerniak B
    Eur Urol; 2016 Oct; 70(4):611-620. PubMed ID: 26988609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.